UK Biobank (core renewal)
Lead Research Organisation:
UK Biobank
Department Name: UNLISTED
Abstract
UK Biobank is supported by The Wellcome Trust, The National Institute of Health Research, The Medical Research Council, The British Heart Foundation and Cancer Research UK. The figures presented on this record represent the Medical Research Council funding contribution only with some additional UKRI Infrastructure funds in addition.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
Technical Summary
The UK Biobank resource has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. There are now sufficient numbers of incident cases of the commoner conditions to support extensive and powerful research into their determinants.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
Organisations
People |
ORCID iD |
Rory Collins (Principal Investigator) |
Publications
Zhong H
(2023)
Causal relationships between mood instability and autoimmune diseases: A mendelian randomization analysis.
in Autoimmunity reviews
Tubbs JD
(2021)
Modeling Parent-Specific Genetic Nurture in Families with Missing Parental Genotypes: Application to Birthweight and BMI.
in Behavior genetics
Hugh-Jones D
(2022)
Human Capital Mediates Natural Selection in Contemporary Humans.
in Behavior genetics
Williams CM
(2023)
A General Cognitive Ability Factor for the UK Biobank.
in Behavior genetics
Verhulst B
(2021)
Using Genetic Marginal Effects to Study Gene-Environment Interactions with GWAS Data.
in Behavior genetics
Pasman JA
(2022)
Genetic Risk for Smoking: Disentangling Interplay Between Genes and Socioeconomic Status.
in Behavior genetics
Domingue BW
(2022)
Modeling Interaction and Dispersion Effects in the Analysis of Gene-by-Environment Interaction.
in Behavior genetics
Pasman JA
(2022)
The CADM2 Gene and Behavior: A Phenome-Wide Scan in UK-Biobank.
in Behavior genetics
Cheesman R
(2020)
Familial Influences on Neuroticism and Education in the UK Biobank.
in Behavior genetics
Rayner C
(2019)
Genetic influences on treatment-seeking for common mental health problems in the UK biobank.
in Behaviour research and therapy
De Lange AG
(2021)
Prominent health problems, socioeconomic deprivation, and higher brain age in lonely and isolated individuals: A population-based study.
in Behavioural brain research
Thangaraj PM
(2020)
Comparative analysis, applications, and interpretation of electronic health record-based stroke phenotyping methods.
in BioData mining
Sun X
(2021)
Identification of significant genes and therapeutic agents for breast cancer by integrated genomics.
in Bioengineered
Speed D
(2022)
SNP-based heritability and selection analyses: Improved models and new results.
in BioEssays : news and reviews in molecular, cellular and developmental biology
Wang V
(2023)
Syllable-PBWT for space-efficient haplotype long-match query
in Bioinformatics
Kirchler M
(2022)
transferGWAS: GWAS of images using deep transfer learning
in Bioinformatics
Lin MF
(2021)
Sparse Project VCF: efficient encoding of population genotype matrices.
in Bioinformatics (Oxford, England)
Westerman KE
(2021)
GEM: scalable and flexible gene-environment interaction analysis in millions of samples.
in Bioinformatics (Oxford, England)
McInnes G
(2019)
Global Biobank Engine: enabling genotype-phenotype browsing for biobank summary statistics.
in Bioinformatics (Oxford, England)
Zhuang Y
(2022)
Incorporating family disease history and controlling case-control imbalance for population-based genetic association studies.
in Bioinformatics (Oxford, England)
Gai L
(2018)
Finding associated variants in genome-wide association studies on multiple traits.
in Bioinformatics (Oxford, England)
Zhang D
(2020)
Fast and robust ancestry prediction using principal component analysis.
in Bioinformatics (Oxford, England)
Majumdar A
(2021)
A two-step approach to testing overall effect of gene-environment interaction for multiple phenotypes.
in Bioinformatics (Oxford, England)
Naseri A
(2019)
Efficient haplotype matching between a query and a panel for genealogical search.
in Bioinformatics (Oxford, England)
Sapin E
(2021)
Novel approach for parallelizing pairwise comparison problems as applied to detecting segments identical by decent in whole-genome data.
in Bioinformatics (Oxford, England)
Pividori M
(2019)
ukbREST: efficient and streamlined data access for reproducible research in large biobanks.
in Bioinformatics (Oxford, England)
Quick C
(2019)
emeraLD: rapid linkage disequilibrium estimation with massive datasets.
in Bioinformatics (Oxford, England)
Privé F
(2020)
Efficient toolkit implementing best practices for principal component analysis of population genetic data.
in Bioinformatics (Oxford, England)
Privé F
(2022)
Using the UK Biobank as a global reference of worldwide populations: application to measuring ancestry diversity from GWAS summary statistics.
in Bioinformatics (Oxford, England)
Dey P
(2022)
Outlier detection for multi-network data.
in Bioinformatics (Oxford, England)
Wertenbroek R
(2022)
XSI-a genotype compression tool for compressive genomics in large biobanks.
in Bioinformatics (Oxford, England)
St-Pierre J
(2023)
Efficient penalized generalized linear mixed models for variable selection and genetic risk prediction in high-dimensional data.
in Bioinformatics (Oxford, England)
Nam Y
(2023)
Discovering comorbid diseases using an inter-disease interactivity network based on biobank-scale PheWAS data.
in Bioinformatics (Oxford, England)
Kerin M
(2021)
A non-linear regression method for estimation of gene-environment heritability.
in Bioinformatics (Oxford, England)
Yue W
(2022)
P-smoother: efficient PBWT smoothing of large haplotype panels
in Bioinformatics Advances
Yang L
(2023)
Depression, Depression Treatments, and Risk of Incident Dementia: A Prospective Cohort Study of 354,313 Participants
in Biological Psychiatry
Zhao Y
(2022)
Mesial Prefrontal Cortex and Alcohol Misuse: Dissociating Cross-sectional and Longitudinal Relationships in UK Biobank.
in Biological psychiatry
Wendt FR
(2023)
Sex-Specific Genetic and Transcriptomic Liability to Neuroticism.
in Biological psychiatry
Hatoum AS
(2023)
Genome-wide Association Study Shows That Executive Functioning Is Influenced by GABAergic Processes and Is a Neurocognitive Genetic Correlate of Psychiatric Disorders.
in Biological psychiatry
Lehto K
(2020)
Childhood Adoption and Mental Health in Adulthood: The Role of Gene-Environment Correlations and Interactions in the UK Biobank.
in Biological psychiatry
Maihofer AX
(2022)
Enhancing Discovery of Genetic Variants for Posttraumatic Stress Disorder Through Integration of Quantitative Phenotypes and Trauma Exposure Information.
in Biological psychiatry
Glanville KP
(2020)
Classical Human Leukocyte Antigen Alleles and C4 Haplotypes Are Not Significantly Associated With Depression.
in Biological psychiatry
Schiel JE
(2022)
Associations Between Sleep Health and Amygdala Reactivity to Negative Facial Expressions in the UK Biobank Cohort.
in Biological psychiatry
Ma LZ
(2023)
Cataract, Cataract Surgery, and Risk of Incident Dementia: A Prospective Cohort Study of 300,823 Participants.
in Biological psychiatry
Brazel DM
(2019)
Exome Chip Meta-analysis Fine Maps Causal Variants and Elucidates the Genetic Architecture of Rare Coding Variants in Smoking and Alcohol Use.
in Biological psychiatry
Description | Impact of clinically silent atrial fibrillation on cerebrovascular disease and cognitive decline in the UK Biobank Imaging Cohort |
Amount | £2,474,260 (GBP) |
Funding ID | RG/18/6/33576 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 06/2019 |
End | 06/2024 |
Description | UK Biobank - The Repeat Imaging Project |
Amount | £2,500,000 (GBP) |
Funding ID | R39738/CN039 |
Organisation | MRC Dementias Platform UK |
Sector | Academic/University |
Country | United Kingdom |
Start | 03/2019 |
End | 01/2023 |
Description | UK Biobank - Whole genome sequencing of 50,000 UKB participants |
Amount | £30,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2020 |
Description | UK Biobank- Expansion of the UKB imaging to a 4th centre and repeat imaging assessment of 10,000 participants |
Amount | £8,500,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 12/2022 |
Description | UK Biobank Scientific Conference |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | The UK Biobank Scientific Symposium included presentations about the successes and future plans of the UK Biobank. It took place on 21 June 2018 in London |
Year(s) Of Engagement Activity | 2018 |
Description | UK Biobank participant imaging event |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UK Biobank for participants of the imaging work |
Year(s) Of Engagement Activity | 2021 |
Description | UKBiobank participant events - 2014 - 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UKB Biobank participants regularly attend events aimed at informing them about the work being undertaken with their data. Usually, the events last a few hours and include an overview from the chief scientist and two talks from scientists that have used UKB data. From 2014 - 2020 over 4,000 participants have taken part in events in Edinburgh (4), Manchester (4), Nottingham, Leeds, Cardiff (2), Newcastle (5), Glasgow (2), Bristol (2) and Reading(4). They are often over-subscribed and participants leave these events wishing to seek more information and support he programme in new ways (EG in imaging, genome sequencing) |
Year(s) Of Engagement Activity | 2014,2015,2016,2017,2018,2019 |
URL | http://www.ukbiobank.ac.uk |